Humana (HUM) Q1 2025 earnings summary

Executive summary

• Q1 2025 net income rose to $1.2 billion ($10.30 per diluted share), up from $0.7 billion ($6.11 per share) in Q1 2024, driven by improved benefit and operating cost ratios, value creation initiatives, and strong operational performance.

• Q1 2025 results exceeded plan, with some outperformance attributed to timing-related factors; full-year guidance reaffirmed.

• No changes to 2025 Medicare membership guidance, but expects a decline of about 550,000 due to exits from unprofitable plans and counties.

• Operational progress continues in Stars, clinical excellence, cost management, and capital allocation, with robust growth in CenterWell and Medicaid.

• Litigation regarding CMS 2026 Star Ratings remains unresolved; external environment evolving as expected.

Financial highlights

• Q1 2025 Adjusted EPS rose to $11.58 from $7.23 in Q1 2024; GAAP EPS was $10.30, up from $6.11.

• Adjusted EPS guidance for 2025 reaffirmed at approximately $16.25; GAAP EPS guidance revised to $14.68.

• Q1 2025 consolidated revenues were $32.1 billion, up 8.4% year-over-year, with premiums revenue up 8.0% and services revenue up 25.6%.

• Insurance segment benefit ratio for Q1 2025 was 87.4%, with full-year guidance at 90.1%-90.5%.

• CenterWell contributed about a third of the Q1 beat, driven by PCO and pharmacy, with some favorability potentially durable.

Outlook and guidance

• Full-year 2025 outlook and margin targets reaffirmed, with focus on margin expansion and earnings potential.

• 3% MA margin target remains for 2027, contingent on Stars outcomes.

• Earnings cadence expected to be front-loaded in 2025 due to IRA, with higher Q1 earnings and lower in subsequent quarters.

• Guidance anticipates a doc fix in late Q3 or Q4, which may pressure year-end results.

• Management believes current cash balances, investment securities, operating cash flows, and available credit provide adequate resources for ongoing operations, expansion, and capital needs for at least the next twelve months.